Abstract: Therapeutics and methods of treating COVID-19 comprising in a patient comprising administering to the patient an effective dose of a pharmacologic composition containing a first therapeutic; wherein the first therapeutic is a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment the H2S donor is one of include diallyl trisulfide (DATS), diallyl disulfide (DADS), sodium sulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, a sulfinate, a sulfoxide, a persulfide, a polysulfide, and a sulfone. According to a further embodiment the pharmacologic composition further contains a second therapeutic, wherein the second therapeutic is a nitrite, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment wherein the nitrite is an inorganic nitrite.

Abstract: Therapeutics and methods for treating a stroke in a human comprising administering a therapeutic to the patient, wherein the therapeutic comprises one of immortalized human placenta mesenchymal stem cells (hPMSCs) and a product from the immortalized hPMSCs. Methods and therapeutic products comprising extracellular vesicles (EVs) isolated from of immortalized hPMSCs. Therapeutics and methods of treating COVID-19 disease vascular injury comprising administering a therapeutic to the patient, wherein the therapeutic comprises one of hPMSCs and a product from the hPMSCs.

Abstract: Therapeutics and methods of treating one of an angiotensin-converting enzyme 2 (ACE2) associated condition and an ACE2 associated pre-condition patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes either a Sigmar1 antagonist or any pharmaceutically acceptable salt, solvate, or prodrug thereof, or a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof. A method of treating coronavirus disease 2019 (COVID-19) patient comprising administering to the patient a pharmaceutically therapeutic dose of a therapeutic, wherein the therapeutic includes a Sigmar1 enhancer, or any pharmaceutically acceptable salt, solvate, or prodrug thereof.

Abstract: A method of treating a condition in a mammal comprising: administering a pharmacologically effective amount of a therapeutic; wherein the therapeutic one of decreases EphA2 expression and inhibits ephrin type-A receptor 2; and the condition is a proinflammatory or fibroproliferative condition.

Abstract: A method of treating a condition in a mammal comprising administering a pharmacologically effective amount of a therapeutic, wherein the therapeutic one of increases EphA2 expression and supplements ephrin type-A receptor 2, and the condition is one of fatty liver disease, elevated plasma cholesterol level, and elevated plasma triglyceride level.